After 17 years of research and development, the subsidiary North China Pharmaceutical Company.Ltd(600812) of Jizhong Energy Resources Co.Ltd(000937) Group officially launched the injection of omativumab (trade name: Xunke) on February 12. It makes up for the insufficient supply of rabies passive immune agents in China and has a broad market prospect.
Omativir McAb injection is mainly used for passive immunization against rabies. The drug is a recombinant human anti rabies virus McAb injection developed in China, which can target and neutralize rabies virus in vivo, so as to supplement the antibody blank in the process of active immunization of rabies vaccine.
Yang Yinchao, Secretary of the Party committee and chairman of Jizhong Energy Resources Co.Ltd(000937) group, said in his speech: ” Jizhong Energy Resources Co.Ltd(000937) will take this new product listing as an opportunity to deeply grasp the operation law of the enterprise, fully guide and support North China Pharmaceutical Company.Ltd(600812) to further deepen internal reform, accelerate transformation and upgrading, accelerate the pace of revitalization, and strive to make due contributions to the high-quality development of Hebei and China Meheco Group Co.Ltd(600056) industry.”
Zhang Yuxiang, party secretary and chairman of North China Pharmaceutical Company.Ltd(600812) said that North China Pharmaceutical Company.Ltd(600812) will continue to firmly lead the innovation direction of biological drugs, and timely introduce a batch of antibodies, vaccines and recombinant protein drugs that can be developed in coordination with existing products and technology platforms through strengthening foreign cooperation, so as to form a product population and achieve the leading complementary effect.
It is understood that in recent years, Jizhong Energy Resources Co.Ltd(000937) group has established the development direction of “consolidating and developing the energy industry, strengthening and optimizing the pharmaceutical and health industry, extending and expanding the new chemical material industry and optimizing the lean modern service industry”, and made great efforts to build the industrial pattern of “three main and one auxiliary”. As an important part of the pharmaceutical sector, North China Pharmaceutical Company.Ltd(600812) seize the strategic opportunity of Hebei Province to build a biomedical industry cluster, accelerate the development process of biomedicine, continuously expand the reserve resources of biomedicine, build and complete the echelon biomedical product cluster, and establish eight technology platforms covering the whole chain of biomedical research, development and production The three mainstream expression systems and three biopharmaceutical industrialization bases have realized the synchronous development of the whole chain of biopharmaceutical R & D and production. Xun, however, following the industrialization of recombinant biotech drugs such as recombinant hepatitis B vaccine (CHO cell), Jim Xin, Ji Xin Xin, EPO and so on, North China Pharmaceutical Company.Ltd(600812) has enriched North China Pharmaceutical Company.Ltd(600812) biological medicine product clusters and formed the technological superiority of North China Pharmaceutical Company.Ltd(600812) in the field of monoclonal antibody, which has laid the foundation for Hebei’s biomedicine technology. It has made positive contributions to accelerating Hebei Province to become a strong province in biomedical industry.
It is reported that with the launch of xunco, its upgraded variety of the same series – rabies monoclonal antibody combination preparation has also entered the phase II clinical trial stage. At the same time, a batch of biological drugs such as mg011 and mg021 have started the phase I clinical trial. The relevant quality research of long-acting EPO and recombinant human norovirus vaccine is under way, and more than 10 biological drugs are in different research and development stages, It has formed an echelon layout of biopharmaceutical products. In the future, Jizhong Energy Resources Co.Ltd(000937) group will adhere to the guidance of innovation, unblock diversified scientific and technological investment channels, and cast a high-tech engine for the high-quality development of enterprises.
